

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/012364 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) *C07K 14/315* (2006.01)
A61K 39/09 (2006.01) *A61P 31/04* (2006.01)

(21) International Application Number:

PCT/EP2024/069620

(22) International Filing Date:

11 July 2024 (11.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23185079.3 12 July 2023 (12.07.2023) EP
23190789.0 10 August 2023 (10.08.2023) EP

(71) Applicant: **VIROMETIX AG** [CH/CH]; Wagistrasse 14,
8952 Schlieren (CH).

(72) Inventors: **STERGIOU, Lilli**; Krummackerstrasse 23,
8902 Urdorf (CH). **RODRIGUEZ BALBOA, Javier**;
Brandstrasse 1, 8952 Schlieren (CH). **LAMPROKOS-
TOPOULOU, Agaristi**; Agiou Ioannou 87, 15342 Athens
(GR). **RASSEK, Oliver**; Schönenbergstrasse 24, 8820 Wä-
denswil (CH). **SPOULOU, Vana**; Ethinkis Antistaseos
80E, 14671 Nea Erithrea (GR). **MANSOUR, Marc**; 42
Stone Gate Drive, Halifax, Nova Scotia B3N 3J2 (CA).
DAIKOPOULOU, Vasiliki; Grünaustrasse 6, 8953 Di-
etikon (CH).

(74) Agent: **SPERRLE, Martin**; Latscha Schöllhorn Partner
AG Grellingerstrasse 60, 4052 Basel (CH).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: COMPOSITIONS OF PNEUMOCOCCAL ANTIGENS

(57) Abstract: The present invention relates to a composition comprising a first pneumococcal antigen comprising a first pneumococcal peptide epitope or a nucleic acid encoding said first pneumococcal antigen, a second pneumococcal antigen comprising a second pneumococcal peptide epitope or a nucleic acid encoding said second pneumococcal antigen, and a third pneumococcal antigen comprising a third pneumococcal peptide epitope or a nucleic acid encoding said third pneumococcal antigen, wherein said first pneumococcal peptide epitope is derived from the non-proline block (NPB) of the Pneumococcal surface protein A (PspA), said second pneumococcal peptide epitope is derived from the proline-rich region (PR) of the Pneumococcal surface protein A (PspA), and said third pneumococcal peptide epitope is derived from the surface-exposed pneumococcal protein PhtE of the histidine triad (Pht) protein family.



WO 2025/012364 A1